October 11, 2021 Supernus and Pacira swoop while their targets are down Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
September 27, 2019 Go or no go? Novartis eyes a big new growth driver The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
